Additional studies by the group are evaluating the potential of IRL therapy in similar pathologies in which loss of blood flow is a common theme, including myocardial infarction, stroke and neonatal hypoxic-ischemic encephalopathy. The overall project, which has led to a United States patent, has been supported by other funding mechanisms, including the W.K. Kellogg Foundation, the WSU Technology Transfer initiatives and a pilot grant provided by the WSU Cardiovascular Research Institute.

The grant (15GRNT2440158) is usable through June 2017.